AI Article Synopsis
- RRP12 is a nucleolar protein associated with advanced colorectal cancer (CRC) that contributes to poor patient survival by promoting cancer cell aggressiveness through epithelial-mesenchymal transition (EMT).
- High levels of RRP12 correlate with negative clinical outcomes like lymph node metastasis and advanced tumor stages.
- Targeting RRP12 might offer new therapeutic strategies for managing CRC by inhibiting the EMT process and reducing cancer cell migration and invasion.
Article Abstract
Background: The survival of patients with advanced colorectal cancer (CRC) is variable. The high rates of recurrence, metastasis, and drug resistance make clinical treatment difficult, which needs to further develop therapeutic and prognostic targets. Ribosomal RNA processing 12 homolog (RRP12), as a nucleolar protein involved in ribosome subunit maturation and export, plays important roles in cell cycle-related processes and the response to DNA damage, and regulates the occurrence and development of various cancers. The primary aim of this study was to identify the function of RRP12 in the process of epithelial-mesenchymal transition (EMT) in CRC.
Methods: In this study, the expression of RRP12 in tissue samples and the association with clinicopathological features in CRC was evaluated, and the correlation between RRP12 expression and aggressiveness of CRC was detected. After knockdown of RRP12 gene, the relationship between RRP12 and EMT-related indicators was verified and of CRC cells. Identification of RRP12-related genes and pathways through bioinformatic-based analyses was performed to find its potential mechanism.
Results: RRP12 is highly expressed in CRC cell lines and clinical samples and is associated with poor survival in CRC patients. RRP12 expression was positively associated with lymph node metastasis, tumor-node-metastasis (TNM) stage, and poor differentiation. Knockdown of RRP12 was found to suppress migration and invasion of CRC cells. RRP12 contributed to the EMT process of CRC cell lines in a ZEB1-mediated manner. RRP12 knockdown was found to reverse metastasis of CRC cells . Bioinformatic-based analyses indicated that RRP12 could serve as a potential biomarker for prognostic assessment of CRC patients.
Conclusions: RRP12 is involved in the tumorigenesis and metastasis of CRC by regulating the EMT process through ZEB1. Thus, RRP12 could be a potential therapeutic target for CRC therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643574 | PMC |
| http://dx.doi.org/10.21037/jgo-23-254 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of alternative lengthening of telomeres-related genes prognosis model in hepatocellular carcinoma.
BMC Cancer
November 2024
Department of Intensive Medicine (Comprehensive Intensive Care Unit), The First Affiliated Hospital of Gannan Medical University, No. 128 Jin Ling Lu, Ganzhou, Jiangxi, 341000, P.R. China.
Background: Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, characterized by high mortality. This study aimed to explore the prognostic value and function of alternative lengthening of telomeres (ALT)-related genes in HCC.
Methods: Differentially expressed genes (DEGs) were identified based on The Cancer Genome Atlas (TCGA) and then intersected with ALT-related genes to obtain ALTDEGs.
Real-world impacts from a decade of Quality Enhancement Research Initiative-partnered projects to translate the Diabetes Prevention Program in the Veterans Health Administration.
Health Serv Res
December 2024
VA Center for the Study of Healthcare Innovation, Implementation & Policy, Los Angeles, California, USA.
Objectives: To describe the impacts of four Veterans Health Administration (VA) Quality Enhancement Research Initiative (QUERI) projects implementing an evidence-based lifestyle intervention known as the Diabetes Prevention Program (DPP).
Data Sources And Study Setting: 2012-2024 VA administrative and survey data.
Study Design: This is a summary of findings and impacts from four effectiveness-implementation projects focused on in-person and/or online DPP across VA sites.
Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study.
Nucleosides Nucleotides Nucleic Acids
June 2024
Department of Medical Biology, School of Medicine, Usak University, Usak, Turkey.
Imatinib (IMA) and nilotinib are the first and second generations of BCR-ABL tyrosine kinase inhibitors, which widely applied in chronic myeloid leukemia (CML) treatment. Here we aimed to provide new targets for CML treatment by transcriptome analysis. Microarray data GSE19567 was downloaded and analyzed from Gene Expression Omnibus (GEO) to identify common genes, which are downregulated or upregulated in K562-imatinib and K562-nilotinib treated cells.
View Article and Find Full Text PDFRRP12 suppresses cell migration and invasion in colorectal cancer cell via regulation of epithelial-mesenchymal transition.
J Gastrointest Oncol
October 2023
Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, China.
Article Synopsis
- RRP12 is a nucleolar protein associated with advanced colorectal cancer (CRC) that contributes to poor patient survival by promoting cancer cell aggressiveness through epithelial-mesenchymal transition (EMT).
- High levels of RRP12 correlate with negative clinical outcomes like lymph node metastasis and advanced tumor stages.
- Targeting RRP12 might offer new therapeutic strategies for managing CRC by inhibiting the EMT process and reducing cancer cell migration and invasion.
Potential prognostic biomarkers of hepatocellular carcinoma based on 4D label-free quantitative proteomics analysis pilot investigation.
Int J Biol Markers
March 2024
Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian, China.
Background: Hepatocellular carcinoma carries a poor prognosis and poses a serious threat to global health. Currently, there are few potential prognostic biomarkers available for the prognosis of hepatocellular carcinoma.
Methods: This pilot study used 4D label-free quantitative proteomics to compare the proteomes of hepatocellular carcinoma and adjacent non-tumor tissue.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!